The objective of this study was to perform a systematic review and meta-analysis of the predictive value of late gadolinium enhancement (LGE) cardiac magnetic resonance (CMR) for future cardiovascular events and death in hypertrophic cardiomyopathy (HCM).
H ypertrophic cardiomyopathy (HCM) is the most common inherited cardiovascular disease that is characterized by substantial heterogeneity with respect to presentation, phenotypic expression, clinical course, and overall prognosis (1-3) Although HCM is the leading cause of sudden death (SCD) in young people, it has a diverse phenotypic spectrum such that the clinical presentation can occur during any phase of life, and the vast majority of HCM patients with SCD have few to no clinical symptoms (1) . In general, HCM confers an annual mortality rate of about 1%, but a subset of roughly 10% to 20% of patients have higher mortality or morbidity due to complications arising from SCD (perhaps as high as 5% annually), progressive heart failure (HF), and atrial fibrillation complicated by embolic stroke (1) .
Device therapy with implantable cardioverterdefibrillators (ICD) has been shown to be an extremely effective intervention for primary prevention of sudden death in patients with HCM (4) . There are 5 clinically accepted high-risk factors for SCD that may justify primary prevention with ICD: 1) a family history of 2 or more premature sudden deaths; 2) extreme left ventricular hypertrophy (Ն30 mm); 3) unexplained syncope in young patients; 4) nonsustained ventricular tachycardia (NSVT) on Holter monitoring in patients Յ30 years of age; and 5) an abnormal blood pressure response during upright exercise (4, 5) . However, in a large HCM ICD registry, only 13% of patients with prophylactic primary prevention devices implanted for high-risk features had an appropriate discharge for ventricular tachycardia or ventricular fibrillation, whereas 25% of these patients had inappropriate ICD shocks (6) . Furthermore, the risk of appropriate ICD discharge was not significantly different for 1, 2, or 3 of the traditional clinical risk factors (6) . This highlights the importance of improved methods for SCD risk stratification in HCM patients.
Another substantial complication of HCM is progressive HF, as roughly 15% to 20% of HCM patients with heart failure have marked symptom progression (New York Heart Association [NYHA] functional classes III and IV) (1) . Determining which HCM patients are at a higher risk for the development and progression of HF could identify those who stand to benefit from more aggressive HF medical therapy than currently indicated as well as provide prognostic information regarding HF death.
Cardiac magnetic resonance (CMR) is emerging as a powerful tool for the diagnosis and risk stratification in HCM. It is widely accepted as a gold standard method for assessment of myocardial function as well as left ventricular (LV) mass, which has been shown to be a sensitive predictor of adverse outcomes in HCM (7) . As myocardial fibrosis may provide the underlying arrhythmogenic substrate in HCM, there has been significant interest in using late gadolinium enhancement (LGE) to evaluate myocardial fibrosis. Multiple studies have demonstrated a high prevalence of LGE, predominantly in a patchy, multifocal mid-wall distribution in regions of hypertrophy (8, 9) ; and LGE has been shown to be associated with NSVT as well as with other risk factors for SCD (9 -12) . Furthermore, the presence of LGE has been shown to be a marker of adverse outcomes in multiple nonischemic cardiomyopathies (13, 14) . Only recently have studies emerged evaluating LGE for the prediction of endpoints of cardiovascular death and SCD in HCM; however, these recent studies have been limited in size and demonstrate differing results (15) (16) (17) (18) . The objective of this meta-analysis is to determine the association of LGE by CMR in patients with HCM for the prediction of cardiac mortality, SCD/aborted SCD, HF death, and all-cause mortality. That could potentially identify patients who are at risk for SCD who may benefit from prophylactic ICD therapy, as well as providing prognostic information for predicting HCM death.
M E T H O D S
Data sources. We searched PubMed/ MEDLINE, the Cochrane Database of Systemic Reviews, Cochrane Methodology Register, Cochrane Controlled Trials Register, and the ISI Web of Science to identify studies for meta-analysis inclusion. We used the text words and related Medical Subject Headings for hypertrophic cardiomyopathy and magnetic resonance imaging. There were no language restrictions, as non-English publications were included in initial search designs and evaluated. Study selection. Two physician investigators independently conducted the literature search and extraction of relevant titles. The titles and abstract of potentially relevant studies and review articles were screened for appropriateness before retrieval of the full article, where relevant. The PubMed search (Fig. 1 ). Of these, 572 were excluded by title or abstract as unrelated to the scientific question. Twenty studies were retrieved for detailed evaluation, 3 of which were review articles that were excluded. Of the 17 potentially appropriate studies, only 4 studies evaluated the selected endpoints (cardiac death, SCD, and HF death) in HCM patients using LGE by CMR. These 4 studies were then included in the meta-analysis. Only 2 of the studies reported on all-cause mortality and were analyzed separately for this endpoint. Data abstraction and validity assessment. Two physician investigators independently abstracted data using a standardized form. We extracted the following demographic data: author, year of publication, design, follow-up duration, sample size, characteristics of LGE CMR used, age, percentage male, NYHA functional class I, NYHA functional class II, NYHA functional class III/IV, LVEF Յ50%, LVEF, wall thickness Ͼ30 mm, syncope, sustained ventricular tachycardia/fibrillation, family history of SCD, and LGE status. Clinical outcomes included the raw events data for all-cause mortality, all cardiac deaths, SCD/aborted SCD, SCD, and HF death. When disagreements occurred among data extractors, the final decision was made by consensus of all authors. Statistical analysis. All statistical analyses were performed using the Comprehensive Meta Analysis program (Biostat, Englewood, New Jersey). Data were analyzed according to the intention-to-treat principle. The Cochrane Q statistic and I2 statistic was calculated to assess heterogeneity among the trials. The Q statistic and I2 statistic failed to indicate statistical heterogeneity for any endpoint. The odds ratio (OR) for each study was recalculated from raw event data. Based upon the lack of heterogeneity in the studies, we chose to use a fixed-effects model. A summary OR was calculated using a fixed-effects model from the OR and the 95% confidence interval (CI) for each endpoint in each study using Mantel-Haenszel methods. To assess publication bias, we generated a funnel plot of the logarithm of effect size and compared it with the standard error for each trial. A p value Ͻ0.05 was considered statistically significant.
R E S U L T S
A focused PubMed literature search only yielded 4 CMR studies with LGE that included data on the clinical endpoints of cardiovascular mortality, SCD or aborted SCD, and HF death. The data from these 4 studies was pooled together (total of 1,063 patients), and the endpoints were reanalyzed through pooled OR to evaluate the association of LGE with these endpoints. All 4 studies reported on SCD, cardiac death, and HF death. Cardiac death included both SCD and HF death in 3 of the studies, whereas the study by Maron et al. (18) did not have any cases of HF death. Aborted SCD was deemed as appropriate ICD discharge in 1 study, and 2 studies defined SCD as appropriate ICD therapies, whereas Bruder et al. (15) incorporated a broader definition of aborted SCD. Only 2 studies reported all-cause mortality, and these studies were analyzed separately for this endpoint. A query of the LGE techniques utilized in all included studies found that a 1.5T scanner with 6-mm to 10-mm section thickness were used to acquire delayed enhancements images 10 to 15 min after the intravenous administration of 0.1 to 0.2 mmol/kg of gadolinium-based contrast agent using a breath-hold 2-dimensional segmented inversion-recovery sequence. All acquisitions were consistent with Society for Cardiovascular Magnetic Resonance published guidelines (19) . Table 1 shows the inclusion and exclusion criteria and primary endpoints evaluated in each of these studies. Three of these studies were prospective cohort studies of HCM patients, whereas the study by Rubinshtein et al. (17) was a retrospective analysis from a database of patients who had undergone CMR Four studies met criteria for inclusion; 13 studies were excluded because of lack of information related to the chosen clinical endpoints (cardiac death, sudden cardiac death [SCD], aborted SCD, and heart failure [HF] death), and 3 studies were excluded because they were review articles.
with LGE assessment (15) (16) (17) (18) (18) did not specifically report on HF death. The baseline characteristics from these studies, as well as the pooled characteristics are shown in Table 2 . Overall, 1,063 patients were included in the meta-analysis; 64% of the subjects were male, and the mean age across all of the studies was 52 years. The study by Maron et al. (18) had a younger mean age of 42 years. Across all studies, 17% of patients had NYHA functional class III/IV HF; however, the study by Rubinshtein et al. (17) had a higher prevalence of severe HF (29%). There was a high prevalence of LGE in these studies, averaging 60% (range 55% to 67%) of the subjects. Three of the studies had an average follow-up period of at least 3.0 years, but the study by Maron et al. (18) had an average follow-up period of only 1.9 years. These 4 studies demonstrated differing results with respect to the primary outcomes (cardiac death, HF death, SCD, aborted SCD, and all-cause mortality) evaluated in this meta-analysis. The study by Maron The LGE had a statistically significant association with this combined primary endpoint (hazard ratio of 3.4, p ϭ 0.006) (16) . This study showed a weak trend for predicting cardiovascular mortality (p ϭ 0.163) but was underpowered for this endpoint. The study did not demonstrate any difference in SCD as a function of the presence of LGE (16) .
The study by Bruder et al. (15) demonstrated that LGE on CMR was significantly associated with both all-cause mortality (OR: 5.47), and cardiac mortality (OR: 8.01) (15) ; and LGE emerged from multivariable analysis as an independent predictor of mortality in HCM patients, as LGE was present in 15 of the 16 patients who had a significant cardiac event (sudden death, suspected sudden death, aborted sudden death, or All-cause mortality, cardiac mortality CAD ϭ coronary artery disease; CE ϭ contrast enhanced; CMR ϭ cardiac magnetic resonance; ECG ϭ electrocardiogram; HCM ϭ hypertrophic cardiomyopathy; ICD ϭ implantable cardioverter-defibrillator; IV ϭ intravenous; LV ϭ left ventricular; MRI ϭ magnetic resonance imaging; SCD ϭ sudden cardiac death; VF ϭ ventricular fibrillation; VT ϭ ventricular tachycardia.
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HF) (15) . The extracted outcomes of interest for this meta-analysis from these studies are presented in Table 3 .
The meta-analysis shows that LGE was significantly associated with cardiac death (pooled OR: 2.92, 95% CI: 1.01 to 8.42; p ϭ 0.047) ( Fig. 2A) over a mean follow-up of 3.1 years. Overall, 31 of the 634 HCM patients with LGE on CMR had cardiac death (4.9%), whereas only 5 of the 429 patients (1.2%) without LGE had cardiac death. There was a trend toward an association between LGE and sudden death/aborted sudden death (pooled OR: 2.39, 95% CI: 0.87 to 6.58; p ϭ 0.091) (Fig. 2B) . The presence of LGE on CMR was associated with a 3.9% risk of sudden death/aborted death (25 of 634 subjects), but only 5 of the 429 subjects (1.2%) without LGE experienced sudden death/aborted sudden death. The meta-analysis demonstrated a significant association between the presence of LGE and HF death (pooled OR: 5.68, 95% CI: 1.04 to 31.07; p ϭ 0.045) as 13 of 634 subjects (2.1%) with LGE on CMR died of HF, but no patients without LGE on CMR went on to die of HF (Fig. 2C) . Although only 2 studies (Bruder et al. [15] and Rubinshtein et al. [17] included data on all-cause mortality, the presence of LGE was associated with all-cause mortality (pooled OR: 4.46, 95% CI: 1.53 to 13.01; p ϭ 0.006) (Fig. 2D) . Table 4 summarizes the pooled OR for all endpoints analyzed in this meta-analysis. The funnel plot of effect size versus study precision demonstrated no asymmetry to suggest major publication bias.
D I S C U S S I O N
This systematic review and meta-analysis demonstrates that LGE on CMR is significantly associated with cardiac death, HF death, and all-cause mortality in HCM, in addition to a trend toward an association with sudden death/aborted sudden death. These findings support the argument that LGE on CMR should be considered as an independent predictor of adverse cardiac outcomes in HCM. The ability to more accurately predict which HCM patients without current clinically accepted risk factors are at high risk for developing cardiac death, SCD, or HF death could have important implications for the care of these patients. These patients would be potentially identified for more aggressive medical and device therapy than is currently clinically indicated (such as institution of renin-aldosterone system inhibition for prevention of HF or ICD placement for primary prevention of SCD), and could potentially impact the morbidity and mortality associated with HCM.
Elliott et al. (21) studied the use of traditional noninvasive risk factors to identify high-risk HCM patients that warrant ICD placement for primary SCD prevention and followed up 368 patients (65% Pooled indicates average or sum across all studies as appropriate for data. LVEF ϭ left ventricular ejection fraction; NYHA ϭ New York Heart Association; NR ϭ not reported; other abbreviations as in Table 1 . Pooled indicates average or sum across all studies as appropriate for data. HF ϭ heart failure; LGE ϭ late gadolinium enhancement; other abbreviations as in Tables 1 and 2 .
LGE by CMR in HCM male) for an average of 3.6 Ϯ 2.5 years. Multivariate SCD risk ratios for 5 of the traditional risk factors ranged from 1.8 to 5.3, as patients without any of the 5 risk factors had an estimated 6-year SCD-free survival rate of 95%, while the presence of 1, 2, or 3 risk factors reduced the SCD-free survival rates to 93%, 82%, and 36%, respectively (21) . They found that patients with 2 or more traditional risk factors had a lower 6-year SCD-free survival rate than patients with only 1 or no risk factors, thus warranting consideration for ICD therapy for primary SCD prevention (21) . This meta-analysis demonstrates that LGE identified the chosen clinical endpoints with similar predictive accuracy (pooled OR ranging from 1.45 to 2.92) as that of the traditional noninvasive risk factors of Elliott et al. (21) .
This meta-analysis has several limitations. First, there have only been a small number of clinical studies that have analyzed the ability of LGE by CMR to identify the clinically relevant endpoints of SCD, HF death, and cardiovascular mortality, and therefore, the total number of patients evaluated remains small and is reflected by the width of the pooled OR confidence intervals. While showing a trend toward the detection of SCD/aborted SCD, this meta-analysis is still underpowered to demonstrate the ability of LGE to predict this important outcome. Second, studies have only included subjects who have not had a prior ICD placement because of the incompatibility of these devices with magnetic resonance imaging. That has biased these clinical studies toward subjects who have fewer risk factors and potentially lower events of SCD, as most of the patients typically have not met criteria for ICD placement previously. Ideally, CMR would be performed at the time of diagnosis so that LGE could be assessed in all patients regardless of their number of traditional risk factors. On the basis of limitations provided by the raw data, we were unable to calculate adjusted OR taking into account the traditional risk factors. Another key limitation is the ability to control for ICD prescription after CMR in the 4 studies, specifically, addressing any 
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Figure 2. Forrest Plots and Pooled Odds Ratios for Clinical Endpoints
The presence of late gadolinium enhancement by cardiac magnetic resonance predicted (A) cardiac death, (C) heart failure (HF) death, and (D) all-cause mortality. Additionally, there was a trend toward significance for (B) prediction of sudden cardiac death (SCD)/aborted SCD. CI ϭ confidence interval. Tables 1  and 3 .
Green et al. Prognostic Value of LGE by CMR in HCM heterogeneity in prescribing practices between the studies' respective centers. The ICDs would likely decrease the incidence of cardiovascular death and SCD, but would not be expected to effect the combined endpoint of SCD/aborted SCD as device interrogation would identify patients with aborted SCD.
The current literature evaluating LGE by CMR has mostly classified the presence or absence of LGE as a binary variable. The high incidence of LGE in HCM seen in this meta-analysis (60% of patients) necessitates the development more sophisticated techniques for quantifying LGE in HCM to potentially improve the prognostic utility of these techniques (20) . Approaches may include using a standardized semiquantitative scoring of LGE utilizing a 17-segment approach (similar to the sum rest score used in nuclear perfusion studies) to quantify overall scar burden. Further investigation to better characterize the implications of the level of LGE present could potentially lead to greater specificity with regard to using LGE to predict outcomes. Additional CMR parameters such as the total scar burden and scar surface area by quantitative analysis might also improve the detection of clinically significant LGE identified on CMR. Previous work by Bello et al. (22) in CAD has shown that once infarct mass is Ͼ10% of LV mass, the risk for death increases 2-fold, and patients with Ն24% scar were at an even higher risk. Infarct surface area and mass have been identified as stronger predictors of risk for monomorphic ventricular arrhythmias than reduced LVEF in patients with coronary artery disease (23) . The ongoing DETERMINE (Defibrillators to Reduce Risk by Magnetic Resonance Imaging Evaluation) trial will evaluate ICD therapy in patients with ischemic cardiomyopathy with mild-moderate systolic LV dysfunction (LVEF 35% to 50%) and scar burden of Ն10% of LV mass (24) , potentially offering insight into whether ICD discharge correlates with total scar burden and scar surface area. This threshold effect of scar may also have implications in HCM. The ability to accurately access total scar burden through T1 mapping could provide a more objective method of noninvasively quantifying diffuse myocardial fibrosis, as recent studies have validated this method in various myocardial diseases (25, 26) . Additionally, stress perfusion CMR could also be used in HCM to further stratify the risk for SCD. Several studies have looked at single-photon emission computed tomography and its relation to ischemia in HCM, as Sorajja et al. (27) found that ischemia identified by single-photon emission computed tomography in adult HCM patients (average age 60 Ϯ 16 years) was significantly associated with cardiovascular death. The ability of CMR to accurately quantify the extent and severity of ventricular hypertrophy, identify and quantify scar (using LGE or T1 mapping) while also evaluating for inducible ischemia may provide clinicians with a more accurate appraisal of a patient's risk for SCD and other adverse cardiovascular outcomes than traditional risk factors may indicate. An algorithm utilizing various CMR parameters may improve the predictive value in identifying patients that may benefit from ICD placement or other primary prevention strategies.
As previously proposed (20) , a large, prospective registry using a multicenter approach would help to definitively establish LGE and other CMR parameters as a predictor of SCD and cardiac death in HCM. This registry could include various CMR parameters in addition to the assessment of traditional clinical risk factors. The goal of this registry would be to determine whether CMR-derived risk factors provide independent prognostic value over current clinical risk factors for predicting adverse clinical outcomes such as SCD or cardiac death. Although the currently available data clearly show a trend toward an association between LGE and SCD/aborted SCD, the pooled data are still underpowered for detecting this important endpoint and are limited with regard to ability to properly control for traditional risk factors. The ongoing European CMR registry is prospectively evaluating the utility of CMR for risk stratification in HCM patients (28) . This registry, as well as a proposed international CMR registry focused on HCM that is being planned, will provide additional statistical power to definitively address the utility of LGE for predicting SCD.
C O N C L U S I O N S
Overall, LGE on CMR appears to possess significant prognostic power in the prediction of serious cardiac complications in HCM (all-cause mortality, cardiac death, and HF death). Using several CMR parameters may increase the positive predictive value of CMR in identifying patients who should be candidates for a more aggressive treatment approach than is current clinical practice.
